Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a.
Garaci. E E; Lopez. M M; Bonsignore. G G; Della Giulia. M M; D'Aprile. M M; Favalli. C C; Rasi. G G; Santini. S S; Capomolla. E E; Vici. P P
Key Findings
- 24 of 56 patients (2 complete, 22 partial) responded to the treatment
- Median overall survival was 12.6 months
- NK cell activity and lymphocyte counts dropped less with thymosin‑alpha‑1 and interferon than with chemotherapy alone
Practical Outcomes
- The results suggest thymosin‑alpha‑1 may help preserve immune function during aggressive chemotherapy, but the evidence is limited to cancer therapy settings. There’s no direct guidance for using the peptide to boost health or longevity in non‑patient populations, and more rigorous trials are needed before recommending it for everyday biohacking protocols.
Summary
A small clinical trial gave cancer patients a mix of chemotherapy drugs plus the immune‑boosting peptide thymosin‑alpha‑1 and low‑dose interferon. The combo helped shrink tumors in many patients and seemed to protect some immune cells, with side effects that were manageable. However, the study was only in advanced lung‑cancer patients, not healthy people, and it doesn’t give clear dosing or safety info for everyday use.
Abstract
A phase II study was performed to evaluate the clinical and immunological effects of a regimen of cisplatin (DDP) and etoposide (VP-16) combined with thymosin-alpha 1 (TA1) and low-dose interferon-alpha 2a (IFN) in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Chemoimmunotherapy cycles were repeated every 3 weeks. There were 24 responses (two complete, 22 partial) among 56 assessable patients. Median survival was 12.6 months. Overall, treatment was well tolerated. Natural killer cell activity and lymphocyte subtypes were depressed by chemotherapy, but this effect was less prominent in patients receiving TA1 and IFN in comparison with a concomitant group of patients treated with DDP and VP-16 only. The combination of DDP and VP-16 and TA1 and IFN is effective in advanced NSCLC with acceptable toxicity. However, the results of this study need to be confirmed in a randomised trial.
Study Information
pubmed
1995
1995-12-01T00:00:00.000Z
10.1016/0959-8049(95)00477-7
38
13